Abstract
This Viewpoint examines results from the LIGHTSIDE trials for photobiomodulation to treat age-related macular degeneration and raises questions regarding the trial protocols and the efficacy and safety of the therapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have